Filing Flows › Celldex Therapeutics (CLDX) › Product development and licensing agreements revenue
Celldex Therapeutics (CLDX) Product development and licensing agreements revenue by quarter
Celldex Therapeutics' Product development and licensing agreements revenue was $7K in Q2 2026 (second quarter 2026), -82% from Q4 2025. Over the last 5 quarters it ranged from $7K (Q2 2026) to $50K (Q1 2025).
| Quarter | Product development and licensing agreements revenue | Q/Q | Y/Y |
|---|---|---|---|
| Q2 2026 | $7K | -82% | 0% |
| Q4 2025 | $40K | +471% | +400% |
| Q2 2025 | $7K | -86% | — |
| Q1 2025 | $50K | +525% | — |
| Q4 2024 | $8K | — | — |
Q2 2026 at a glance
Celldex Therapeutics, Q2 2026: revenue $22K (-97% year over year), net loss $73.5M, operating cash flow −$57.4M. The chart follows the revenue to costs, profit and cash.
Questions
What is Celldex Therapeutics' Product development and licensing agreements revenue?
Celldex Therapeutics' Product development and licensing agreements revenue was $7K in Q2 2026 (second quarter 2026), -82% from Q4 2025.
How has Celldex Therapeutics' Product development and licensing agreements revenue changed?
Over the last 5 quarters it ranged from $7K (Q2 2026) to $50K (Q1 2025).